Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
Regeneron (REGN)'s dupilumab serves a $20B market. Kymera dosed the first IRF5-directed therapy in human history and its oral drug matched Regeneron's injectable dupilumab in Phase 1b, targeting a $20B market with 48M untreated patients. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE Kymera Therapeutics NASDAQ:KYMR ) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into the clinic. That is not a minor pipeline update. Kymera Therapeutics missed on both revenue and earnings in Q4. Revenue came in at $2.87 million against an estimate of $17.30 million, and EPS landed at -$0.97 versus the -$0.79 estimate. But for a clinical-stage biotech burning cash to build a pipeline, the quarterly collaboration revenue figure is almost beside the point. What matters is what the science is doing. KT-621: Th
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswire
- Kymera Therapeutics (KYMR) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KYMR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hoMarketBeat
- Kymera Therapeutics (KYMR) had its price target raised by UBS Group AG from $90.00 to $128.00. They now have a "buy" rating on the stock.MarketBeat
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 144
- 3/4/26 - Form 4
- KYMR's page on the SEC website